In animal models of AAA induced by hyperlipidemia and angiotensin II, deletion or inhibition of PCSK9 has been found to significantly reduce the formation of AAA lesions, improve survival rates, and decrease systemic inflammation, independent of changes in circulating cholesterol levels [101, 118]. Here, PCSK9 is linked to triple-A syndrome.